ClinicalTrials.gg
CompletedNCT03430843Updated Oct 26, 2024Results posted

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

A Phase 3 interventional study of Tislelizumab and Paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Completed at 104 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.

Enrollment
2nd of 23
512 · median 50
Started
2018
with 1 other
Phase 3
3 of 23
none open now
Registered
1st of 23
by date
Lead sponsor
5 of 23
BeiGene

Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one is the 2nd largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 1st registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 270 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 181 Esophageal Squamous Cell Carcinoma studies recruiting now, 84 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)

Keywords

  • Unresectable
  • metastatic
  • second-line
  • squamous
  • esophagus
  • chemotherapy
  • paclitaxel
  • docetaxel
  • irinotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)
  2. Tumor progression during or after treatment for advanced unresectable / ESCC
  3. At least one measurable/evaluable lesion by (RECIST) v1.1
  4. (ECOG) performance status of 0 or 1 prior to randomization

Key Exclusion Criteria:

  1. Receipt of 2 or more prior systemic treatments for advanced/metastatic unresectable ESCC
  2. History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula within 6 months prior to randomization
  3. Tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of fistula in the study treatment assessed by investigator
  4. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage
  5. Received prior therapies targeting programmed death 1 () or programmed death ligand 1 (PD-L1)
  6. Prior active within the previous 2 years (exceptions include the tumor under investigation in this trial, and locally recurring cancers that have undergone curative treatment, such as resected basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast)
  7. Active brain or .
  8. Has active disease or history of autoimmune diseases at high risk for relapse
  9. Known history of, or any evidence of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis diagnosed based on imaging or clinical findings, or uncontrolled systemic diseases, including diabetes, hypertension, acute lung diseases, etc
  10. Known history of (HIV)
  11. Has cardiovascular risk factors
  12. Pregnant or breastfeeding woman.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
512 participants (actual)

Study arms

  • Experimental
    Tislelizumab

    Tislelizumab on Day 1, given every 21 days

    Drug: Tislelizumab

  • Active comparator
    Investigator chosen chemotherapy (ICC)

    Paclitaxel on Day 1, given every 21 days or on a weekly schedule; OR Docetaxel on Day 1, given every 21 days; OR Irinotecan on Days 1 and 8, given every 21 days

    Drug: Paclitaxel · Drug: Docetaxel · Drug: Irinotecan

Interventions

  • 200 mg administered intravenously (IV)

    Also known as: BGB-A317

  • 135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care

  • 75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan

  • 125 mg/m\^2 administered IV

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set

    OS is defined as the length of time from the date of randomization until the date of death due to any cause in all randomized participants

    Time frame: Approximately 2 years and 10 months from date of first randomization

Secondary outcomes

  1. Overall Survival (OS) in the PDL-1 Positive Analysis Set

    OS is defined as the time from the date of randomization until the date of death due to any cause in the PD-L1 positive population, defined as vCPS ≥10%.

    Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)

  2. Objective Response Rate (ORR) in the ITT Analysis Set

    ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;

    Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)

  3. Overall Response Rate (ORR) in the PD-L1 Positive Analysis Sets

    ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1;

    Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)

  4. Progression-free Survival (PFS) in the ITT Analysis Set

    PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the ITT analysis set

    Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)

  5. Progression-free Survival (PFS) in the PDL-1 Positive Analysis Set

    PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the PDL-1 Positive Analysis Set

    Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)

  6. Duration of Response (DOR) in the ITT Analysis Set

    DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first

    Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)

  7. Duration of Response (DOR) in the PDL-1 Positive Analysis Set.

    DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first

    Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)

  8. Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set

    Mean change from baseline in EORTC QLQ-C30 index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes

    Time frame: Baseline to Cycle 6 (21 days per cycle)

  9. HRQoL as Assessed by EORTC QLQ-C30 in the PDL-1 Positive Analysis Set

    Mean change from baseline in EORTC QLQ-C30 Index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes

    Time frame: Baseline to Cycle 6 (21 days per cycle)

  10. HRQoL as Assessed by EORTC QLQ-Oesophagus Cancer Module (EORTC QLQ-OES18) Reported in ITT Analysis Set

    Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 6 (21 days per cycle)

  11. HRQoL as Assessed by EORTC QLQ-OES18) in the PDL-1 Positive Analysis Set.

    Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 6 (21 days per cycle)

  12. HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Questionnaire (EQ-5D-5L) in the ITT Analysis Set

    Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 6 (21 days per cycle)

  13. HRQoL as Assessed by EQ-5D-5L in the PD-L1 Positive Analysis Set

    Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 6 (21 days per cycle)

  14. Number of Participants Experiencing Adverse Events (AEs)

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs

    Time frame: From the first dose date to 30 days after the last dose date; up to approximately 4 years and 11 months

07

Results

Posted Dec 29, 2023
Limitations and caveats
The impact on treatment was considered very limited due to the small number of patients remaining on treatment, the short COVID-19 restriction period (in Asia), and limited restrictions for healthcare visits (in Europe/North America).

Participant flow

This study was conducted at 132 study centers in Mainland China, Taiwan, United States, France, Italy, Germany, Spain, Japan, South Korea, Belgium and the United Kingdom.

Participant flow — Overall Study
MilestoneTislelizumabInvestigator Chosen Chemotherapy
Started256256
Treated255240
Completed00
Not completed256256
Withdrew: Death233233
Withdrew: Sponsor decision176
Withdrew: Withdrawal by subject514
Withdrew: Lost to follow-up13

Outcome measures

PrimaryOverall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set

OS is defined as the length of time from the date of randomization until the date of death due to any cause in all randomized participants

Time frame:
Approximately 2 years and 10 months from date of first randomization
Reported as:
Median · Months
Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set
MonthsTislelizumabInvestigator Chosen Chemotherapy
Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set8.6 (7.5 to 10.4)6.3 (5.3 to 7.0)
Statistical analysis
  • Tislelizumab vs Investigator Chosen Chemotherapy · 1-sided, Log Rank Test · p = 0.0001 · Hazard ratio (hr): 0.70 · 95% CI 0.57 to 0.85
SecondaryOverall Survival (OS) in the PDL-1 Positive Analysis Set

OS is defined as the time from the date of randomization until the date of death due to any cause in the PD-L1 positive population, defined as vCPS ≥10%.

Time frame:
Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Reported as:
Median · Months
Overall Survival (OS) in the PDL-1 Positive Analysis Set
MonthsTislelizumabInvestigator Chosen Chemotherapy
Overall Survival (OS) in the PDL-1 Positive Analysis Set10.2 (8.5 to 14.5)5.1 (3.8 to 8.2)
SecondaryObjective Response Rate (ORR) in the ITT Analysis Set

ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;

Time frame:
Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) in the ITT Analysis Set
Percentage of ParticipantsTislelizumabInvestigator Chosen Chemotherapy
Objective Response Rate (ORR) in the ITT Analysis Set20.3 (15.6 to 25.8)9.8 (6.4 to 14.1)
SecondaryOverall Response Rate (ORR) in the PD-L1 Positive Analysis Sets

ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1;

Time frame:
Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR) in the PD-L1 Positive Analysis Sets
Percentage of ParticipantsTislelizumabInvestigator Chosen Chemotherapy
Overall Response Rate (ORR) in the PD-L1 Positive Analysis Sets26.3 (17 to 37.3)11.3 (4.7 to 21.9)
SecondaryProgression-free Survival (PFS) in the ITT Analysis Set

PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the ITT analysis set

Time frame:
Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Reported as:
Median · Months
Progression-free Survival (PFS) in the ITT Analysis Set
MonthsTislelizumabInvestigator Chosen Chemotherapy
Progression-free Survival (PFS) in the ITT Analysis Set1.6 (1.4 to 2.7)2.1 (1.5 to 2.7)
SecondaryProgression-free Survival (PFS) in the PDL-1 Positive Analysis Set

PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the PDL-1 Positive Analysis Set

Time frame:
Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Reported as:
Median · Months
Progression-free Survival (PFS) in the PDL-1 Positive Analysis Set
MonthsTislelizumabInvestigator Chosen Chemotherapy
Progression-free Survival (PFS) in the PDL-1 Positive Analysis Set2.7 (1.5 to 4.2)2.3 (1.4 to 3.0)
SecondaryDuration of Response (DOR) in the ITT Analysis Set

DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first

Time frame:
Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Reported as:
Median · Months
Duration of Response (DOR) in the ITT Analysis Set
MonthsTislelizumabInvestigator Chosen Chemotherapy
Duration of Response (DOR) in the ITT Analysis Set7.1 (4.1 to 11.3)4.0 (2.1 to 8.2)
SecondaryDuration of Response (DOR) in the PDL-1 Positive Analysis Set.

DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first

Time frame:
Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Reported as:
Median · Months
Duration of Response (DOR) in the PDL-1 Positive Analysis Set.
MonthsTislelizumabInvestigator Chosen Chemotherapy
Duration of Response (DOR) in the PDL-1 Positive Analysis Set.7.1 (2.9 to 13.2)5.7 (1.2 to NA)
SecondaryHealth-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set

Mean change from baseline in EORTC QLQ-C30 index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes

Time frame:
Baseline to Cycle 6 (21 days per cycle)
Reported as:
Mean · Score on a scale
Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set
Score on a scaleTislelizumabInvestigator Chosen Chemotherapy
Baseline16.2 ± 12.2818.3 ± 13.86
Change at Cycle 60.2 ± 8.284.8 ± 9.38
SecondaryHRQoL as Assessed by EORTC QLQ-C30 in the PDL-1 Positive Analysis Set

Mean change from baseline in EORTC QLQ-C30 Index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes

Time frame:
Baseline to Cycle 6 (21 days per cycle)
Reported as:
Mean · Score on a scale
HRQoL as Assessed by EORTC QLQ-C30 in the PDL-1 Positive Analysis Set
Score on a scaleTislelizumabInvestigator Chosen Chemotherapy
Baseline16.8 ± 10.9618.8 ± 12.02
Change at Cycle 60.5 ± 7.390.5 ± 4.86
SecondaryHRQoL as Assessed by EORTC QLQ-Oesophagus Cancer Module (EORTC QLQ-OES18) Reported in ITT Analysis Set

Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 6 (21 days per cycle)
Reported as:
Mean · Score on a scale
HRQoL as Assessed by EORTC QLQ-Oesophagus Cancer Module (EORTC QLQ-OES18) Reported in ITT Analysis Set
Score on a scaleTislelizumabInvestigator Chosen Chemotherapy
Baseline14.7 ± 11.8116.3 ± 13.20
Change at Cycle 6-0.6 ± 8.633.0 ± 12.05
SecondaryHRQoL as Assessed by EORTC QLQ-OES18) in the PDL-1 Positive Analysis Set.

Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 6 (21 days per cycle)
Reported as:
Mean · Score on a scale
HRQoL as Assessed by EORTC QLQ-OES18) in the PDL-1 Positive Analysis Set.
Score on a scaleTislelizumabInvestigator Chosen Chemotherapy
Baseline16.5 ± 12.6918.1 ± 12.21
Change at Cycle 6-0.9 ± 7.45-2.9 ± 5.16
SecondaryHRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Questionnaire (EQ-5D-5L) in the ITT Analysis Set

Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 6 (21 days per cycle)
Reported as:
Mean · Score on a scale
HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Questionnaire (EQ-5D-5L) in the ITT Analysis Set
Score on a scaleTislelizumabInvestigator Chosen Chemotherapy
Baseline73.7 ± 17.0572.5 ± 18.13
Change at Cycle 6-0.6 ± 14.81-5.9 ± 16.34
SecondaryHRQoL as Assessed by EQ-5D-5L in the PD-L1 Positive Analysis Set

Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 6 (21 days per cycle)
Reported as:
Mean · Score on a scale
HRQoL as Assessed by EQ-5D-5L in the PD-L1 Positive Analysis Set
Score on a scaleTislelizumabInvestigator Chosen Chemotherapy
Baseline74.1 ± 14.8470.5 ± 18.40
Change at Cycle 6-0.5 ± 17.594.4 ± 12.82
SecondaryNumber of Participants Experiencing Adverse Events (AEs)

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs

Time frame:
From the first dose date to 30 days after the last dose date; up to approximately 4 years and 11 months
Reported as:
Number · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsTislelizumabInvestigator Chosen Chemotherapy
Number of participants with TEAEs245236
Number of participants with SAEs109106

Adverse events

Collected over All-cause mortality and adverse events (AEs): up to approximately 4 years and 11 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab233/256 (91%)109/255 (42.7%)232/255 (91%)
Investigator Chosen Chemotherapy (ICC)233/256 (91%)106/240 (44.2%)231/240 (96.3%)
Most frequent serious events
Showing 10 of 137
Most frequent serious events
EventTislelizumabInvestigator Chosen Chemotherapy (ICC)
PneumoniaInfections and infestations19/25517/240
DysphagiaGastrointestinal disorders13/2554/240
Neutrophil count decreasedInvestigations0/25510/240
Febrile neutropeniaBlood and lymphatic system disorders0/2558/240
DiarrhoeaGastrointestinal disorders0/2558/240
White blood cell count decreasedInvestigations0/2558/240
Decreased appetiteMetabolism and nutrition disorders1/2556/240
Oesophageal obstructionGastrointestinal disorders5/2551/240
PneumonitisRespiratory, thoracic and mediastinal disorders5/2552/240
LeukopeniaBlood and lymphatic system disorders0/2554/240
Most frequent other events
Showing 10 of 67
Most frequent other events
EventTislelizumabInvestigator Chosen Chemotherapy (ICC)
AnaemiaBlood and lymphatic system disorders80/255109/240
White blood cell count decreasedInvestigations11/25595/240
Neutrophil count decreasedInvestigations6/25588/240
Decreased appetiteMetabolism and nutrition disorders42/25580/240
DiarrhoeaGastrointestinal disorders32/25575/240
NauseaGastrointestinal disorders37/25572/240
Weight decreasedInvestigations62/25545/240
VomitingGastrointestinal disorders27/25548/240
ConstipationGastrointestinal disorders41/25545/240
FatigueGeneral disorders33/25542/240

Baseline characteristics

Age, Continuous
Age, Continuous(years)TislelizumabInvestigator Chosen ChemotherapyTotal
Mean61.8 ± 8.4161.8 ± 8.0261.8 ± 8.21
Sex: Female, Male
Sex: Female, Male(Participants)TislelizumabInvestigator Chosen ChemotherapyTotal
Female394180
Male217215432
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TislelizumabInvestigator Chosen ChemotherapyTotal
Hispanic or Latino224
Not Hispanic or Latino252252504
Unknown or Not Reported224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TislelizumabInvestigator Chosen ChemotherapyTotal
Race — Asian201207408
Race — White or Caucasian534497
Race — Not Reported101
Race — Unknown123
Race — Black or African American022
Race — Other011
Eastern Cooperative Oncology Group (ECOG) Performance Status Score
Eastern Cooperative Oncology Group (ECOG) Performance Status Score(Participants)TislelizumabInvestigator Chosen ChemotherapyTotal
06661127
1190195385
PD-L1 Expression Status
PD-L1 Expression Status(Participants)TislelizumabInvestigator Chosen ChemotherapyTotal
vCPS >= 10%8062142
vCPS < 10%100122222
Missing7672148
08

Study locations

104 sites
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Toledo Clinic Cancer Center
    Toledo, Ohio 43623, United States
  • Imelda Ziekenhuis Bonheiden
    Bonheiden, 2820, Belgium
  • Cliniques Universitaires Saint Luc
    Brussels, 1200, Belgium
  • Uz Antwerpen
    Edegem, 2650, Belgium
  • University Hospitals Leuven
    Leuven, 3000, Belgium
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • The First Affiliated Hospital, Sun Yat Sen University
    Guangzhou, Guangdong 510080, China
  • The Sixth Affiliated Hospital, Sun Yat Sen University
    Guangzhou, Guangdong 510655, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441021, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • The First Peoples Hospital of Changzhou
    Changzhou, Jiangsu 213000, China
  • Huaian Second Peoples Hospital
    Huaian, Jiangsu 223002, China
  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Nantong Tumor Hospital Branch South
    Nantong, Jiangsu 226000, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • Jiangxi Province Cancer Hospital
    Nanchang, Jiangxi 330029, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The Second Affiliated Hospital of Xian Jiaotong University
    Xian, Shaanxi 710004, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276001, China
  • Weifang Peoples Hospital
    Weifang, Shandong 261000, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • Shanxi Provincial Peoples Hospital
    Taiyuan, Shanxi 030012, China
  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
    Chengdu, Sichuan 610071, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650100, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Chru de Brest Hospital Morvan
    Brest, 29200, France
  • Centre Georges Francois Leclerc
    Dijon, 21079, France
  • Chu Besancon Hopital Jean Minjoz
    Doubs, 25030, France
  • Centre Oscar Lambret
    Lille, 59000, France
  • Hopital Prive Jean Mermoz
    Lyon, 69008, France
  • Icm Val Daurelle
    Montpellier, 34090, France
  • Chu Bordeaux Hopital Haut Leveque
    Pessac, 33600, France
  • Chu de Poitiers Site de La Mileterie
    Poitiers, 86000, France
  • Ico Site Rene Gauducheau
    SaintHerblain, 44805, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Charite Universitatsmedizin Berlin
    Berlin, 13353, Germany
  • Universitares Krebszentrum Leipzig
    Leipzig, 04103, Germany
  • Klinikum Johannes Gutenberg Universitaet Mainz
    Mainz, 55131, Germany
  • Ospedale Di Faenza
    Faenza, 48018, Italy
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
    Meldola, 47014, Italy
  • Azienda Ospedaliero Universitaria San Luigi Gonzaga
    Orbassano, 10043, Italy
  • Aou Pisana, Stabilimento Di Santa Chiara
    Pisa, 56126, Italy
  • Ao Citta Della Salute E Della Scienza Di Torino Presidio O
    Torino, 10126, Italy
  • Akita University Hospital
    Akitashi, Akita 010-8543, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • Nho Shikoku Cancer Center
    Matsuyamashi, Ehime 791-0280, Japan
  • Nho Kyushu Cancer Center
    Fukuokashi, Fukuoka 811-1395, Japan
  • Kobe City Medical Center General Hospital
    Kobe, Hyogo 650-0047, Japan
  • St Marianna University School of Medicine Hospital
    Yokohama, Kanagawa 216-8511, Japan
  • Kindai University Hospital
    Osakasayama, Osaka 589-8511, Japan
  • Osaka International Cancer Institute
    Osakashi, Osaka 541-8567, Japan
  • Osaka University Hospital
    Suitashi, Osaka 565-0871, Japan
  • Osaka Medical and Pharmaceutical University Hospital
    Takatsukishi, Osaka 569-8686, Japan
  • Saitama Cancer Center
    Kitaadachigun, Saitama 362-0806, Japan
  • Shizuoka Cancer Center
    Suntogun, Shizuoka 411-8777, Japan
  • National Cancer Center Hospital
    Chuoku, Tokyo 104-0045, Japan
  • Cancer Institute Hospital of Jfcr
    Kotoku, Tokyo 135-8550, Japan
  • Hiroshima University Hospital
    Hiroshima, 734-8551, Japan
  • Kochi Health Sciences Center
    Kochi, 781-8555, Japan
  • Kyoto University Hospital
    Kyoto, 6068507, Japan
  • Seoul National University Bundang Hospital
    Seongnamsi, Gyeonggi-do 13620, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, Incheon Gwang'yeogsi 21565, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    HwasunGun, Jeollanam-do 58128, Korea, Republic of
  • Asan Medical Center
    Seoul, Seoul Teugbyeolsi 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, Seoul Teugbyeolsi 06351, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Seoul Teugbyeolsi 08308, Korea, Republic of
  • Hospital Del Mar
    Barcelona, 08003, Spain
  • Hospital Universitario Vall Dhebron
    Barcelona, 08035, Spain
  • Institut Catala Doncologia
    Barcelona, 08908, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 8036, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Hm Madrid Sanchinarro
    Madrid, 28050, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, 83301, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • Chi Mei Hospital Liouying
    Tainan, 736, Taiwan
  • National Taiwan University Hospital East Campus
    Taipei, 100225, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • The Christie Hospital
    Greater Manchester, M20 4BX, United Kingdom
  • Guys and St Thomas Hospital Nhs Foundation Trust
    London, SE1 9RT, United Kingdom

Showing the first 100 of 104 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol. 2022 Sep 10;40(26):3065-3076. doi: 10.1200/JCO.21.01926. Epub 2022 Apr 20. Erratum In: J Clin Oncol. 2024 Feb 1;42(4):486. doi: 10.1200/JCO.23.02629. PubMed 35442766 ↗
  • Van Cutsem E, Kato K, Ajani J, Shen L, Xia T, Ding N, Zhan L, Barnes G, Kim SB. Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life. ESMO Open. 2022 Aug;7(4):100517. doi: 10.1016/j.esmoop.2022.100517. Epub 2022 Jul 1. PubMed 35785595 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2020, 34 months.

Results were first posted in Dec 2023, 3 years after primary completion. A results delay was requested in Nov 2021.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Feb 13, 2018
StartActual
Jan 26, 2018
Primary completionActual
Dec 1, 2020
CompletionActual
Dec 28, 2022
Results delay requested
Nov 23, 2021
Results first posted
Dec 29, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03430843
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Feb 13, 2018
Start date
Jan 26, 2018
Primary completion
Dec 1, 2020
Completion
Dec 28, 2022
Results posted
Dec 29, 2023
Last update
Oct 26, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion